Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II/III Trial of Radiotherapy Plus Concomitant and Adjuvant Temozolomide With or Without Hydroxychloroquine, Rapamycin for Newly Diagnosed Glioblastoma

NCT03008148 is registered in ClinicalTrials.gov with Johnpro Biotech, Inc. as lead sponsor.

NCT NCT03008148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03008148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II/III Trial of Radiotherapy Plus Concomitant and Adjuvant Temozolomide With or Without Hydroxychloroquine, Rapamycin for Newly Diagnosed Glioblastoma
Lead sponsor
Johnpro Biotech, Inc.
Phase
Phase 2/3
Overall status
Unknown status
Start date
October 11, 2018
Completion date
April 30, 2025
Enrollment
288 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma